SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together ... - PR Newswire
SOPHiA GENETICS and Boundless Bio collaborate to develop an ecDNA detection algorithm for clinical trial enrollment in Boundless Bio's POTENTIATE Phase 1/2 study of BBI-355, an ecDNA-directed therapy for oncogene amplified cancers. Precision for Medicine supports the trial with its laboratory services, contributing to a novel workflow for patient sample processing.
Highlighted Terms
Related News
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together ... - PR Newswire
SOPHiA GENETICS and Boundless Bio collaborate to develop an ecDNA detection algorithm for clinical trial enrollment in Boundless Bio's POTENTIATE Phase 1/2 study of BBI-355, an ecDNA-directed therapy for oncogene amplified cancers. Precision for Medicine supports the trial with its laboratory services, contributing to a novel workflow for patient sample processing.